Thomas H. Oliphant
- Infectious Diseases top 5%
- Clinical Biochemistry top 1%
- Epidemiology top 10%
- Critical Care and Intensive Care Medicine top 2%
- Pharmacology top 10%
- Co-authors
- Sue CammarataRichard G. WunderinkEric RubinsteinMarin H. KollefVu LeEthan RubinsteinJack S. RemingtonRaúl Istúriz
- Topics
- Antimicrobial Resistance in Staphylococcus (4 papers)Cholesterol and Lipid Metabolism (2 papers)Pneumonia and Respiratory Infections (2 papers)
- Cited by
- Applied Microbiology and BiotechnologyClinical BiochemistryCritical Care and Intensive Care Medicine
- Journals
- Clinical Infectious DiseasesAmerican Journal of EpidemiologyAntimicrobial Agents and Chemotherapy
- Partner nations
- United StatesIsraelUnited Kingdom
In The Last Decade
Thomas H. Oliphant
9 papers receiving 757 citations
Peers
Comparison fields: 5 of 71
- Infectious Diseases 543
- Clinical Biochemistry 318
- Epidemiology 269
- Critical Care and Intensive Care Medicine 190
- Pharmacology 155
Countries citing papers authored by Thomas H. Oliphant
This map shows the geographic impact of Thomas H. Oliphant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas H. Oliphant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas H. Oliphant more than expected).
Fields of papers citing papers by Thomas H. Oliphant
This network shows the impact of papers produced by Thomas H. Oliphant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas H. Oliphant. The network helps show where Thomas H. Oliphant may publish in the future.
Co-authorship network of co-authors of Thomas H. Oliphant
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas H. Oliphant. A scholar is included among the top collaborators of Thomas H. Oliphant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas H. Oliphant. Thomas H. Oliphant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 178 | |
| 3 | 148 | |
| 4 | 57 | |
| 5 | 351 | |
| 6 | 12 | |
| 7 | 42 | |
| 8 | 3 | |
| 9 | Patterns of relapse following chemotherapy in non-Hodgkin's lymphoma | 1 |
| 10 | 4 |
About Thomas H. Oliphant
Thomas H. Oliphant is a scholar working on Critical Care and Intensive Care Medicine, Infectious Diseases and Molecular Medicine, having authored 10 papers that have together received 797 indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (4 papers), Cholesterol and Lipid Metabolism (2 papers) and Pneumonia and Respiratory Infections (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (107 citations), Clinical Biochemistry (318 citations) and Critical Care and Intensive Care Medicine (190 citations). Thomas H. Oliphant has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include Sue Cammarata, Richard G. Wunderink, Eric Rubinstein, Marin H. Kollef, Vu Le, Ethan Rubinstein, Jack S. Remington, Raúl Istúriz, Barry Hafkin and Leon G. Smith. Their work appears in journals such as Clinical Infectious Diseases, American Journal of Epidemiology and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.